Cardiometabolic Health Congress (CMHC)
Avatar

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

By Cardiometabolic Health Congress (CMHC) FEATURING Lance Sloan
June 17, 2019
2 Comments
Login to view comments. Click here to Login

Featured Video

08:59
Novo Nordisk – GLP-1 RA Therapy

GLP-1 RA as a First Injectable: What Is the Safety and Efficacy of Two Dif…

Feat. R. Pratley

Featured Video

08:19
Novo Nordisk – GLP-1 RA Therapy

T2D Treatment After Metformin: What Does This GLP-1 RA Head-to-Head Trial …

Feat. R. Pratley

Related Content

AUTOPLAY
06:38
Allan Jaffe

What Does Elevated Troponin Mean in COVID-19?

64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

Primer on Diabetes Management

Feat. S. Inzucchi
18:43
ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century - Almo…

Feat. R. DeFronzo
26:01
Cardiology Fiesta 2017

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibition

Feat. R. DeFronzo
21:19
Patricia Kao

Cardio-Renal Syndrome Management: What Are the Key Factors That Impair Ren…

15:33
Ken Fujioka

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a…

17:35
San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians

Recognizing and Treating HFpEF: How Helpful Are MRAs, ARNi and SGLT2 Inhib…

Feat. B. Greenberg
12:23
American Heart & Vascular Institute

SGLT2 Inhibitors for HF: Is this Therapy Helpful for Reducing the Hospital…

Feat. M. Tipton
11:50
American Heart & Vascular Institute

New Medications for Heart Failure: SGLT2 Inhibitors and Vericiguat. Where …

Feat. M. Kittleson
13:42
George Bakris

Current Status of Prevention and Treatment of Diabetic Nephropathy

10:02
Emory Diabetes Education Training Academy

Insulin Treatment in Patients with Type 2 Diabetes: When to Use Combinatio…

Feat. G. Umpierrez
15:25
Javed Butler

SGLT2 Inhibitors and Heart Failure in Type-2 Diabetes Mellitus

13:48
Courage and Innovation Symposium: Heart Failure & Heart Transplantation

SGLT2 Inhibitors: Not Just for Diabetics Anymore

Feat. R. Lavelle, Pharmd
20:56
Stanford Medicine

COVID-19 & Diabetes Treatment: Can We Reduce the Risk of Poorer Outcom…

Feat. A. Peters
12:47
Northwestern Medicine Cardiovascular Care

15th Annual Heart Failure Holiday Symposium: Highlights and Takeaways

Feat. J. Wilcox, J. Rich, K. Grady, C. Yancy, N. Sweitzer
10:53
4th Annual Cardiovascular Conference: Advances in Cardiovascular Disease - from Prevention to Intervention

SGLT2 Antagonists: How Has Their Role Expanded?

Feat. E. Gianos
09:24
Cardiometabolic Health Congress (CMHC)

SGLT-2 Inhibitors & GLP-1 RAs in CV Risk: What Have We Learned From CV…

Feat. R. Eckel
09:38
George Bakris

Hyperkalemia in Chronic Kidney Disease

07:12
Mayo Clinic Proceedings

Hyperkalemia in CKD: What Benefits do Sodium Zirconium Cyclosilicate and P…

Feat. B. Palmer
14:52
Richard Pratley

Highlights From the 81st ADA Scientific Sessions: The AMPLITUDE Study